Clinical Trials

Clinical Trial Number: EMERGE 402

To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)

Study ID: EMERGE 402
Phase IV
Physician Investigator(s)
Study Locations

To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice.

Eligibility Criteria

Inclusion Criteria:

  • Patient has initiated or will be receiving Zepzelca treatment in line with the local Zepzelca prescribing information.
  • Decision to initiate treatment with Zepzelca was made as per investigator's routine treatment practice prior to enrollment in the study.
  • Patient, or a legally acceptable representative, signed the informed consent before any study-related activities are undertaken.

Exclusion Criteria:

  • Patients who discontinued a prior Zepzelca treatment due to adverse events.
  • Patient who received more than 2 cycles of Zepzelca treatment in their current treatment schedule.
  • Patient received treatment with any investigational agent within 30 days prior to first Zepzelca infusion or plans to use another investigational agent while receiving Zepzelca.